Skip to main content
Premium Trial:

Request an Annual Quote

Genoway Licenses Bluebird's Genetic Modification Technology

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French biotech Genoway said today it has licensed technology from Bluebird Bio to genetically modify rodents.

The license grants Genoway exclusive worldwide rights to Bluebird's RCME technology, which combines a recombinase system with genetic modification, enabling the introduction of a DNA sequence at a specific locus. The technology was developed at the Massachusetts Institute of Technology.

According to Genoway, based in Lyon, France, targeted insertion has now replaced most classic transgenic models, and RCME is an essential tool in the making of knock-in rodents.

Financial and other terms of the deal were not disclosed.

Bluebird develops gene therapies and has offices in Cambridge, Mass., and Paris. Genoway develops genetically modified and research models for the bio-pharmaceutical, chemical, agrochemical, and food industry.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.